You are being redirected because this document is part of your ASTM Compass® subscription.
    This document is part of your ASTM Compass® subscription.

    MONO6-2ND

    Chapter 11 | Bone Graft Substitutes: A Regulatory Perspective

    Published: Nov 2014


      Format Pages Price  
    PDF (1.21 MB) 21 $25   ADD TO CART

    Cite this document

    X Add email address send
    X
      .RIS For RefWorks, EndNote, ProCite, Reference Manager, Zoteo, and many others.   .DOCX For Microsoft Word


    Abstract

    Various synthetic bone graft substitutes, demineralized bone matrix (DBM), bone morphogenetic proteins (BMPs), allogeneic bone cells, and mesenchymal stem cells (MSCs) currently are legally marketed bone graft substitutes; however, each of these products has a distinct regulatory classification and, as such, requires a different regulatory path for approval before marketing. This chapter provides the readers with a rudimentary review of the classification of medical devices, the mechanisms by which a manufacturer may commercialize a medical device, and the current regulatory status of various bone graft substitutes available on the U.S. market.

    Keywords:

    bone graft substitutes, medical device, premarket notification, premarket approval, humanitarian device exemption


    Author Information:

    Jiang, Tao
    Institute for Regenerative Engineering, University of Connecticut Health Center, School of Medicine, Farmington, CT

    The Raymond and Beverly Sackler Center for Biomedical, Biological, Physical and Engineering Sciences, University of Connecticut Health Center, School of Medicine, Farmington, CT

    Department of Medicine, Division of Endocrinology, University of Connecticut Health Center, School of Medicine, Farmington, CT

    Gadaleta, Sergio J.
    Becton Dickinson, Franklin Lakes, NJ


    Committee/Subcommittee: F04.02

    DOI: 10.1520/MONO62014000211